Background: Perimenopausal depression has been attributed to physiological progressive estrogen decline. Estrogen and derivatives have some mood-enhancing effects, although studies of using estrogen as an antidepressant have had mixed results. The gonadomimetic drug tibolone stimulates estrogen receptors in a tissue-selective fashion, increasing the gonadal activity without causing some of the usual side effects of other estrogen preparations.
Methods: A total of 31 postmenopausal outpatients with a major depressive disorder (MDD) participated in the study. Sixteen received the antidepressant fluoxetine (20 mg/day) plus tibolone (2.5 mg/day), and 15 received the same dose of fluoxetine plus placebo, assigned in a randomized fashion.
Results: After 8 weeks of treatment, the two groups had a similar level of improvement in their depressive symptoms. Both treatments were well tolerated, without significant side effects. Pretreatment and posttreatment serum hormonal levels did not predict the final response.
Conclusions: Combining tibolone and fluoxetine did not represent a more robust antidepressant response than fluoxetine alone in postmenopausal women with MDD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/154099903321154121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review and meta-analysis of the effects of progestins on depression in post-menopausal women: An evaluation of randomized clinical studies that used validated questionnaires.
Maturitas
November 2024
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health, University of Genoa, 16132 Genova, GE, Italy; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale San Martino, 16132 Genoa, GE, Italy.
Article Synopsis
- This systematic review examines the effects of progestins as part of hormone therapy on depressive symptoms in postmenopausal women, focusing on various validated depression assessment scales.* -
- It analyzed 16 randomized clinical trials and found that adding progestins to estrogen hormone therapy did not worsen depressive symptoms and could improve them over time, although similar improvements were noted with estrogen alone.* -
- The review concluded that while progestins can be effective, the combination of estrogen with fluoxetine may lead to even greater reductions in depressive symptoms compared to hormones alone.*
Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms.
Cureus
January 2024
Department of Pain Medicine, Paolo Procacci Foundation, Rome, ITA.
An average of 60-80% of all menopausal women experience bothersome vasomotor symptoms (VMSs), such as flushing and sweating, within the first seven years of onset. However, despite increasing prevalence, these hot flashes remain hard to treat and have a negative effect on the quality of life. Though hormone replacement therapy is commonly utilized as a standard treatment for VMSs, this therapy is not recommended for all women.
View Article and Find Full Text PDFPharmacological interventions and hormonal therapies for depressive symptoms in peri- and post-menopausal women: a network meta-analysis of randomized controlled trials.
Psychiatry Res
August 2023
Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung City, Taiwan. Electronic address:
Although significant portion of women experience depressive symptoms during or after menopausal transition, there has been considerable controversy over the benefits of hormone replacement therapy (HRT) and antidepressants due to insufficient evidence supporting the superiority of either treatment. This frequentist model based network meta-analysis (NMA) included randomized controlled trials (RCTs) of menopausal depression symptoms management in menopausal women. Seventy RCTs involving a total of 18,530 women (mean age 62.
View Article and Find Full Text PDFAdvantages and Disadvantages of Using St. John's Wort as a Treatment for Depression.
Cureus
September 2022
Research, Larkin Community Hospital, South Miami, USA.
Background And Objectives: St. John's wort (SJW) extracts are currently being used to treat depression of various degrees of severity. While many studies have shown it to be superior to placebo, data regarding the effectiveness of using SJW as a stand-alone treatment compared with standard antidepressants has yet to be proven conclusively.
View Article and Find Full Text PDFCitalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.
Arch Gynecol Obstet
December 2022
Laboratorio de Bioingeniería de Tejidos, Departamento de Estudios de Posgrado E Investigación [DEPI] de La Facultad de Odontología, Universidad Nacional Autónoma de México [UNAM], 04510, Mexico City, Mexico.
Purpose: This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women.
Methods: A parallel prospective randomized clinical trial was conducted in 91 postmenopausal women with a total score on the Menopause Rating Scale (MRS) ≥ 17 and with the clinical diagnosis of VSM and GSM. Patients were randomly assigned to receive citalopram (n = 49) or fluoxetine (n = 42).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!